## **Core Concept**
Malignant hyperthermia (MH) is a life-threatening medical emergency that occurs in response to certain volatile anesthetics and depolarizing muscle relaxants. It is a pharmacogenetic disorder, meaning it is triggered by specific drugs in susceptible individuals. The condition leads to a hypermetabolic state, muscle rigidity, and a high fever.

## **Why the Correct Answer is Right**
The correct answer, **Succinylcholine and Halothane**, are both well-known triggers for malignant hyperthermia. Succinylcholine is a depolarizing muscle relaxant, and halothane is a volatile anesthetic. Both of these agents can trigger MH in susceptible individuals by causing an abnormal release of calcium from the sarcoplasmic reticulum, leading to sustained muscle contraction and hypermetabolism. The genetic predisposition often involves mutations in the **ryanodine receptor type 1 (RyR1)** or **calsequestrin 1 (CASQ1)** genes.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While certain volatile anesthetics and depolarizing agents can trigger MH, not all combinations are equally risky. For instance, some agents not listed may have a lower risk but are not specified here.
- **Option B:** This option might include agents that are not commonly associated with MH or are less potent triggers compared to succinylcholine and halothane.
- **Option C:** Similar to Option A, the risk varies among anesthetic agents, and some may not be as strongly associated with MH as succinylcholine and halothane.

## **Clinical Pearl / High-Yield Fact**
A crucial point to remember is that malignant hyperthermia can be effectively treated with **dantrolene**, a specific antidote that inhibits calcium release from the sarcoplasmic reticulum. Early recognition and prompt treatment are critical to reduce mortality. MH susceptibility can be screened for in patients with a family history, but not all cases are predictable.

## **Correct Answer:** . Succinylcholine and Halothane